Evidence map›Paper›PMID 39736699›Full record

ArticleCell & bioscience2024

Unraveling the protein kinase C/NDRG1 signaling network in breast cancer.

C Saponaro, M Damato, E Stanca, S Aboulouard, F A Zito, S De Summa, D Traversa, L Schirosi, S Bravaccini, F Pirini and 16 more

Abstract read
In one paragraph

Article in Cell & bioscience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Insight into the Regulation of NDRG1 Expression.International journal of molecular sciences · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

C SaponaroPathology Department, IRCCS Istituto Tumori "Giovanni Paolo II", 70124, Bari, Italy.ORCID http://orcid.org/0000-0002-8196-3583
M DamatoDepartment of Experimental Medicine, University of Salento, Lecce, Italy.ORCID http://orcid.org/0000-0003-0104-4323
E StancaDepartment of Experimental Medicine, University of Salento, Lecce, Italy.ORCID http://orcid.org/0000-0002-0087-1231
S AboulouardLaboratoire Protéomique, Réponse Inflammatoire et Spectrométrie de Masse (PRISM), Lille University, Inserm, CHU Lille, U1192, Lille, France.ORCID http://orcid.org/0000-0002-2045-4785
F A ZitoPathology Department, IRCCS Istituto Tumori "Giovanni Paolo II", 70124, Bari, Italy.ORCID http://orcid.org/0000-0003-4140-4020
S De SummaMolecular Diagnostics and Pharmacogenetics Unit, IRCCS Istituto Tumori "Giovanni Paolo II", 70124, Bari, Italy.ORCID http://orcid.org/0000-0001-9607-3754
D TraversaMolecular Diagnostics and Pharmacogenetics Unit, IRCCS Istituto Tumori "Giovanni Paolo II", 70124, Bari, Italy.ORCID http://orcid.org/0000-0003-0030-2394
L SchirosiPathology Department, IRCCS Istituto Tumori "Giovanni Paolo II", 70124, Bari, Italy.ORCID http://orcid.org/0000-0001-7898-1273
S BravacciniDepartment of Medicine and Surgery, University of Enna "Kore", 94100, Enna, Italy.ORCID http://orcid.org/0000-0002-0075-8538
F PiriniBiosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.ORCID http://orcid.org/0000-0002-7629-2439
E FonziUnit of Biostatistics and Clinical Trials, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.ORCID http://orcid.org/0000-0001-8389-8220
M TebaldiUnit of Biostatistics and Clinical Trials, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.ORCID http://orcid.org/0000-0003-0717-2748
M PuccettiAzienda Unità Sanitaria Locale di Imola, Imola, Italy.ORCID http://orcid.org/0009-0001-1476-3194
A GaballoCNR Nanotec, Institute of Nanotechnology, Via Monteroni, 73100, Lecce, Italy.ORCID http://orcid.org/0000-0003-2104-1568
L PantaloneLaboratory of Cancer Pathology, Center for Advanced Studies and Technology (CAST), "G. d'Annunzio" University of Chieti-Pescara, Chieti, Italy.ORCID http://orcid.org/0000-0002-4212-8251
M RonciLaboratory of Cancer Pathology, Center for Advanced Studies and Technology (CAST), "G. d'Annunzio" University of Chieti-Pescara, Chieti, Italy.ORCID http://orcid.org/0000-0002-0797-6087
L MagnaniThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.ORCID http://orcid.org/0000-0003-1864-4085
D SergiDepartment of Radiology, V. Fazzi Hospital, 73100, Lecce, Italy.
A TinelliDepartment of Obstetrics and Gynecology and CERICSAL, (CEntro di RIcerca Clinico SALentino), "Veris Delli Ponti Hospital", 73020, ScorranoScorrano (Lecce), Italy.ORCID http://orcid.org/0000-0001-8426-8490
S TacconiDepartment of Biology and Biotechnology "Charles Darwin", Sapienza University of Rome, P.Le Aldo Moro 5, 00185, Rome, Italy.ORCID http://orcid.org/0000-0001-7424-1251
L SiculellaDepartment of Experimental Medicine, University of Salento, Lecce, Italy.ORCID http://orcid.org/0000-0002-6890-3674
A M GiudettiDepartment of Biological and Environmental Sciences and Technologies (DiSTeBA), University of Salento, Lecce, Italy.ORCID http://orcid.org/0000-0002-9204-040X
I FournierLaboratoire Protéomique, Réponse Inflammatoire et Spectrométrie de Masse (PRISM), Lille University, Inserm, CHU Lille, U1192, Lille, France.ORCID http://orcid.org/0000-0003-1096-5044
M SalzetLaboratoire Protéomique, Réponse Inflammatoire et Spectrométrie de Masse (PRISM), Lille University, Inserm, CHU Lille, U1192, Lille, France.ORCID http://orcid.org/0000-0003-4318-0817
M Trerotola *Laboratory of Cancer Pathology, Center for Advanced Studies and Technology (CAST), "G. d'Annunzio" University of Chieti-Pescara, Chieti, Italy. marco.trerotola@unich.it.ORCID http://orcid.org/0000-0003-1855-7002
D Vergara *Department of Biological and Environmental Sciences and Technologies (DiSTeBA), University of Salento, Lecce, Italy. daniele.vergara@unisalento.it.ORCID http://orcid.org/0000-0002-2396-7674

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

N-myc downstream-regulated gene 1 (NDRG1) is a member of the NDRG family of intracellular proteins and plays a central role in a wide range of biological processes including stress response, differentiation, and metabolism. The overexpression of NDRG1 is an indicator of poor prognosis in various types of cancer. Here, we found that NDRG1 is an independent prognostic marker of poor outcome in breast cancer (BC). Analysis of the TCGA dataset showed a significant positive correlation between NDRG1 and PRKCA expression, suggesting a mechanistic role of protein kinase C (PKC) in the regulation of NDRG1. We then assessed the hypothesis that PKC might modulate the activity of NDRG1, and observed that different acute stress conditions converging on PKC activation lead to enhanced NDRG1 expression. This mechanism was found to be specific for NDRG1 as the expression of other NDRG members was not affected. Moreover, CRISPR-based inhibition of NDRG1 expression was obtained in a BC cell line, and showed that this protein is a key driver of BC cell invasion through the Rho-associated coiled-coil containing protein kinase 1 (ROCK1)/phosphorylated cofilin pathway that regulates stress fiber assembly, and the modulation of extracellular matrix reorganization related genes. Together, our findings highlight the potential of NDRG1 as a new BC biomarker and uncover a novel mechanism of regulation of NDRG1 expression that might lead to innovative therapeutic strategies.

Indexed as

Breast cancerNDRG1PKCTNBC

Identifiers

PMID39736699
PMCPMC11686873

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.